30345-85-8

Upstream product

• 14856-79-2 N-benzyl(trimethylsilyl)amine 
• 79-37-8 oxalyl dichloride 
• 91360-74-6 N-Benzyl-N'-(trimethylsilyl)carbodiimid 
• 3287-99-8 benzylamine hydrochloride 

Downstream Products

• 1294400-89-7 3-(3-benzyl-2,4,5-trioxo-imidazolidin-1-yl)-propionamide 
• 34582-50-8 2-Phenyl-5-benzyl-hydantoinsaeure 
• 1086764-89-7 C₁₄H₁₄N₂O₄ 
• 1086764-86-4 4-[(3-benzylureido)methyl]benzoic acid 
• 1086764-74-0 C₁₃H₁₂N₂O₅ 
• 128043-60-7 ethyl (3-benzyl-2,4,5-trioxo-imidazolidin-1-yl)ethanoate 

Relevant academic research and scientific papers

Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5- trioxoimidazolidine-1-acetic acids

A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)IC50(AR) was > 1000 in some compounds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5- trioxoimidazolidine-1-acetic acid (NZ-314) was selected as the candidate for clinical development.

Pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof

Pharmaceutical compositions containing imidazolidinetrione derivatives or pharmaceutically acceptable salts thereof having hypoglycemic and hypolipidemic effects. The compositions comprise as an active ingredient at least one imidazolidinetrione derivative of the formula: STR1 wherein each of R1 and R2, which may be the same or different, is hydrogen, an alkyl group, a cycloalkyl group or STR2 and each of R3 and R4, which may be the same or different, is hydrogen, halogen, a nitro group, a lower alkyl group or a lower alkoxy group.